We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Biomarkers Analyzed for Central Nervous System Lymphoma

By Labmedica International staff writers
Posted on 29 Oct 2019
Print article
Image: A histopathology of primary central nervous system lymphoma showing small purple cells along the blood vessel in the brain (Photo courtesy of Columbia University Medical Center).
Image: A histopathology of primary central nervous system lymphoma showing small purple cells along the blood vessel in the brain (Photo courtesy of Columbia University Medical Center).
Primary central nervous system lymphoma (PCNSL) is a rare type of extranodal non-Hodgkin lymphoma (NHL) accounting for 3% of all newly diagnosed primary intracranial tumors. In patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge.

A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of Central Nervous System Lymphoma (CNSL) and their effects on CNSL cells remain unclear.

Neurologists at the Ludwig Maximilians University (Munich, Germany) and their colleagues analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, they serially measured their levels during chemotherapy and relapse. Furthermore, they analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays.

Enzyme-linked immunosorbent assay (ELISA) kits for APRIL were obtained from BioLegend and ELISA kits for BAFF were obtained from R&D Systems. Other methods used in the study included culturing cell lines, survival assays and chemotaxis assays where migrated cells were counted on a Gallios Flow Cytometer.

The scientists reported that CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during methotrexate (MTX) treatment and mediated chemotaxis of malignant B cells.

The authors concluded that CSF levels of APRIL could help establishing the diagnosis of CNSL, especially if stereotactic biopsy is impossible or not conclusive. Moreover, APRIL can serve as a therapeutic marker during therapy and relapse. The study was published on October 15, 2019, in the Journal of Hematology & Oncology.

Related Links:
Ludwig Maximilians University


Print article

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.